Characteristics and Treatments of Patients with Peripheral Arterial Disease Referred to UK Vascular Clinics: Results of a Prospective Registry

European Journal of Vascular and Endovascular Surgery

Volumn 33, Issue 4, 2007, Pages 442-450

  Khan, S ^a   Flather, M ^b,c   Mister, R ^b,d   Delahunty, N ^b   Fowkes, G ^e   Bradbury, A ^f   Stansby, G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antiplatelet agents; Claudication; General practice; Peripheral arterial disease; Risk factors; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINE; NITRATE; ORAL ANTIDIABETIC AGENT; QUININE; WARFARIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLAUDICATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DEMOGRAPHY; DIABETES MELLITUS; DISEASE REGISTRY; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL EDUCATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT REFERRAL; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TOBACCO DEPENDENCE; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTIHYPERTENSIVE AGENTS; BENCHMARKING; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RECURRENCE; REFERRAL AND CONSULTATION; REGISTRIES; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 33847407569     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2006.11.010     Document Type: Article

References (47)

1. Fowkes F.G., Housley E., Cawood E.H., Macintyre C.C., Ruckley C.V., and Prescott R.J. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20 2 (1991) 384-392
2. Selvin E., and Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States:results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110 6 (2004) 738-743
3. Criqui M.H. Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol 88 7B (2001) 43J-47J
4. Smith G.D., Shipley M.J., and Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 82 6 (1990) 1925-1931
5. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 6 (1992) 381-386
6. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 295 5 (2006) 547-553
7. Cassar K., Coull R., Bachoo P., Macaulay E., and Brittenden J. Management of secondary risk factors in patients with intermittent claudication. Eur J Vasc Endovasc Surg 26 3 (2003) 262-266
8. McDermott M.M., Hahn E.A., Greenland P., Cella D., Ockene J.K., Brogan D., et al. Atherosclerotic risk factor reduction in peripheral arterial diseases: results of a national physician survey. J Gen Intern Med 17 12 (2002) 895-904
9. Burns P., Gough S., and Bradbury A.W. Management of peripheral arterial disease in primary care. BMJ 326 7389 (2003) 584-588
10. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 31 1 Pt 2 (2000) S1-S296
11. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 11 (2001) 1317-1324
12. Belch J.J., Topol E.J., Agnelli G., Bertrand M., Califf R.M., Clement D.L., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 8 (2003) 884-892
13. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and DagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
14. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 9374 (2003) 2005-2016
15. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 26 1 (2003) 1-16
16. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 7329 (2002) 71-86
17. Brown M.J., Cruickshank J.K., Dominiczak A.F., MacGregor G.A., Poulter N.R., Russell G.I., et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 17 (2003) 81-86
18. Newman A.B., Sutton-Tyrrell K., Vogt M.T., and Kuller L.H. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 270 4 (1993) 487-489
19. Sutton K.C., Wolfson Jr. S.K., and Kuller L.H. Carotid and lower extremity arterial disease in elderly adults with isolated systolic hypertension. Stroke 18 5 (1987) 817-822
20. Williams B., Poulter N., Brown M.J., Davis M., McInnes G.T., Potter J.F., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J Hum Hypertens 18 (2004) 139-185
21. Ostergren J., Sleight P., Dagenais G., Danisa K., Bosch J., Qilong Y., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25 1 (2004) 17-24
22. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 9489 (2005) 895-906
23. Radack K., and Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151 9 (1991) 1769-1776
24. Ingolfsson I.O., Sigurdsson G., Sigvaldason H., Thorgeirsson G., and Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol-the Reykjavik Study. J Clin Epidemiol 47 11 (1994) 1237-1243
25. Smith F.B., Lowe G.D., Lee A.J., Rumley A., Leng G.C., and Fowkes F.G. Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication. J Vasc Surg 28 1 (1998) 129-135
26. Cole C.W., Hill G.B., Farzad E., Bouchard A., Moher D., Rody K., et al. Cigarette smoking and peripheral arterial occlusive disease. Surgery 114 4 (1993) 753-756
27. Lepantalo M., and Lassila R. Smoking and occlusive peripheral arterial disease. Clinical review. Eur J Surg 157 2 (1991) 83-87
28. Kannel W.B., Skinner Jr. J.J., Schwartz M.J., and Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 41 5 (1970) 875-883
29. Hirsch A.T., Treat-Jacobson D., Lando H.A., and Hatsukami D.K. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 2 3 (1997) 243-251
30. Jonason T., and Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 221 3 (1987) 253-260
31. Scholte op Reimer W., de Swart E., De Bacquer D., Pyorala K., Keil U., Heidrich J., et al. Smoking behaviour in European patients with established coronary heart disease. Eur Heart J 27 1 (2006) 35-41
32. Lancaster T., and Stead L.F. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2 (2005) CD001292
33. Ludvig J., Miner B., and Eisenberg M.J. Smoking cessation in patients with coronary artery disease. Am Heart J 149 4 (2005) 565-572
34. National Institute for Health and Clinical Excellence. Smoking cessation - bupropion and nicotine replacement therapy. Technology appraisal no.39.
35. Gordon T., and Kannel W.B. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA 221 7 (1972) 661-666
36. Fowkes F.G., Housley E., Riemersma R.A., Macintyre C.C., Cawood E.H., Prescott R.J., et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 135 4 (1992) 331-340
37. Robless P., Mikhailidis D.P., and Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 88 6 (2001) 787-800
38. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 9038 (1996) 1329-1339
39. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 16 (2006) 1706-1717
40. Pedersen T.R., Kjekshus J., Pyorala K., Olsson A.G., Cook T.J., Musliner T.A., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 81 3 (1998) 333-335
41. Aronow W.S., Nayak D., Woodworth S., and Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 92 6 (2003) 711-712
42. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 12 (2003) 1481-1486
43. Baigent C K.A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
44. Murabito J.M., Evans J.C., Larson M.G., Nieto K., Levy D., and Wilson P.W. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 163 16 (2003) 1939-1942
45. Zheng Z.J., Sharrett A.R., Chambless L.E., Rosamond W.D., Nieto F.J., Sheps D.S., et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131 1 (1997) 115-125
46. Khan S., Cleanthis M., Smout J., Flather M., and Stansby G. Life-style modification in peripheral arterial disease. Eur J Vasc Endovasc Surg 29 1 (2005) 2-9
47. Burns P., Lima E., and Bradbury A.W. Second best medical therapy. Eur J Vasc Endovasc Surg 24 5 (2002) 400-404